Cashu FinanceCashu Finance
  • Terminal
  • Spotlight
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. KURA

Market Cap: $855.8M

KI

Kura Oncology, Inc.

KURA
NASDAQUSD
Purchase KURA
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

$9.62
+$0.01(0.10%)
At close: Oct 26, 22:20 EDT

Recently from Cashu

Kura Oncology Reports Strong Q4 Earnings and Progress in Drug Development Strategy

Kura Oncology Reports Encouraging Q4 Earnings and Strategic Developments Kura Oncology recently releases its fourth-quarter earnings results, showing promising advancements in both its financial perfo…

Cashu Finance·8 months ago

Kura Oncology Prepares for Earnings Report Amid Advancements in Cancer Therapeutics

Kura Oncology Charts Progress in Cancer Therapeutics with Upcoming Earnings Report As Kura Oncology approaches its quarterly earnings report scheduled for March 5, 2026, the company finds itself at a…

Cashu Finance·8 months ago

Kura Oncology Prepares for Earnings Report Amid Promising Cancer Therapy Developments

Kura Oncology Advances Innovative Cancer Therapies Amid Positive Earnings Insights Kura Oncology, a biopharmaceutical company focused on developing innovative cancer therapies, prepares to release its…

Cashu Finance·8 months ago

Kura Oncology: Leading Innovations in Immunotherapy for Blood Cancers

### Kura Oncology: Advancements in Immunotherapy for Blood Cancers Kura Oncology is positioned at the forefront of cancer treatment advancements, particularly in the realm of immunotherapy. The compan…

Cashu Finance·11 months ago

Open

$11.03

Prev. Close

$9.61

High

$11.13

Low

$10.72

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

CEOTroy Wilson
SectorHealthcare
IndustryBiotechnology
Employees260
IPO DateSep 16, 2015
ExchangeNASDAQ
Exchange NameNASDAQ
CurrencyUSD
Headquarters & Contact
Address4930 Directors Place
City / State / ZIPSan Diego, CA, 92121
CountryUnited States
Phone858 500 8800
Websitehttps://kuraoncology.com